Lineage Cell Therapeutics (LCTX) Tops Q3 EPS by 1c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $1.25 million versus the consensus estimate of $2.6 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Barclays sees global expansion intact, warns against market complacency
• Rank One Computing (ROC) Reiterated at Buy by Benchmark
• Darden Restaurants stock slips premarket despite Q4 earnings beat